Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlodipine/ezetimibe/losartan/rosuvastatin - Hanmi Pharmaceutical

Next Previous
Drug Profile

Amlodipine/ezetimibe/losartan/rosuvastatin - Hanmi Pharmaceutical

Alternative Names: Amosartan XQ; HCP-1701

Latest Information Update: 02 Jun 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antihyperlipidaemics; Antihypertensives; Azetidines; Biphenyl compounds; Dihydropyridines; Fluorobenzenes; Heart failure therapies; Imidazoles; Ischaemic heart disorder therapies; Propanols; Pyrimidines; Small molecules; Sulfonamides; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dyslipidaemias; Hypertension

Most Recent Events

  • 16 Jul 2019 Phase-III clinical trials in Dyslipidaemias in South Korea (PO) (NCT04074551)
  • 16 Jul 2019 Phase-III clinical trials in Hypertension in South Korea (PO) (NCT04074551)
  • 24 Aug 2018 Phase-I clinical trials in Dyslipidaemias (In volunteers) in South Korea (PO) after August 2018

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top